Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles

Journal of Biomedical Nanotechnology
Xiaoshuang ZhuChangxian Dong

Abstract

Infantile hemangiomas are the most common tumors affecting children. Although infantile hemangiomas are benign, they could result in morbidity and mortality. The only US Food and Drug Administration-approved drug for infantile hemangiomas is propranolol hydrochloride (Hemangeol™); however, its adverse effects and high frequency of administration hamper its clinical application. Vascular endothelial growth factor receptor (VEGFR) is crucial to the angiogenesis of infantile hemangiomas, and thus it is considered a valuable therapeutic target for infantile hemangiomas. To reduce the adverse effects and high administration frequency of propranolol, we developed propranolol-loaded nanoparticles conjugated with anti-VEGFR antibody (PNP-VEGFR) as a controlled- and targeted-release system to treat infantile hemangiomas. The characteristics, anti-hemangioma activity, and mechanisms of PNP-VEGFR were examined in vitro and in vivo. The developed PNP-VEGFR exhibited a small size (∼100 nm), drug encapsulation efficiency (∼60%), and sustained drug release for 8 days. PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic eff...Continue Reading

Citations

Oct 4, 2019·Current Drug Metabolism·Siyu GuanJihui Tang
Dec 7, 2018·Pediatric Emergency Care·Robert A FinkelsteinFrancine Blei
Aug 14, 2019·Bioconjugate Chemistry·Yanyan HuaiPriyabrata Mukherjee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.